Hamidreza Montazeri Aliabadi

department of biomedical and pharmaceutical sciences

H指数:26

被引数:3,083

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Charge modulation of peptide/nucleic acid complexes: an anionic additive enhances gene silencing and CRISPR/Cas9 editing by promoting intracellular nucleic acid release

肽/核酸复合物的电荷调控：阴离子添加剂通过促进细胞内核酸释放增强基因沉默和CRISPR/Cas9编辑

Frontiers in Nanotechnology

IF3.8

2026-09-100

Correction: Mandal et al. Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell Lines. Pharmaceutics 2023, 15, 666

更正：Mandal et al. 修改的线性肽可有效沉默乳腺癌和卵巢癌细胞系中的STAT-3。Pharmaceutics 2023, 15, 666

Pharmaceutics 2025, Vol. 17, Page 1324

IF0

2025-10-130

OAAI

Modifying peptide/lipid-associated nucleic acids (PLANAs) for CRISPR/ Cas9 ribonucleoprotein delivery

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2024-04-013

Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell Lines

PHARMACEUTICS

IF5.5

2023-02-162

OAAI

Combinational silencing of components involved in JAK/STAT signaling pathway

JAK/STAT信号通路相关元件的联合沉默

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2022-08-017

[(WR)8WKβA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin

[(WR) 8wk β A]-阿霉素结合物: 一种克服阿霉素多重耐药性的递送系统

CELLS

IF5.2

2022-01-1611

OAAI

Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity

混合环线性肽-阿霉素缀合物的设计和应用作为克服阿霉素耐药性和毒性的策略

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2021-12-0124

PREAI

Suppression of Human Coronavirus 229E Infection in Lung Fibroblast Cells via RNA Interference

FRONTIERS IN NANOTECHNOLOGY

IF3.8

2021-04-275

A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies

用于将siRNA递送到多种乳腺癌细胞系的脂质聚合物的系统比较: 体外研究

ACTA BIOMATERIALIA

IF9.6

2020-01-0117

PREAI

Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs

人乳腺癌细胞对分子靶向药物反应的异质性和可塑性

FRONTIERS IN ONCOLOGY

IF3.3

2019-10-1512

OAAI

Do We Know Jack About JAK? A Closer Look at JAK/STAT Signaling Pathway

我们知道杰克的事吗？JAK/STAT信号通路的进一步研究

FRONTIERS IN ONCOLOGY

IF3.3

2018-07-31324

OAAI

Synthesis, characterization, and in vitro cytotoxicity of fatty acyl-CGKRK-chitosan oligosaccharides conjugates for siRNA delivery

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

IF8.5

2018-06-0121

PREAI

Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research

EXPERT OPINION ON DRUG DELIVERY

IF5.4

2018-01-0126

PREAI

Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells

ACTA BIOMATERIALIA

IF9.6

2018-01-0132

PRE

A systematic approach to JAK/STAT pathway shut-down

MOLECULAR CANCER THERAPEUTICS

IF5.5

2018-01-010

PRE

Difatty Acyl-Conjugated Linear and Cyclic Peptides for siRNA Delivery

ACS OMEGA

IF4.3

2017-10-1922

OAAI

Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates

SCIENTIFIC REPORTS

IF3.9

2017-07-2128

OAAI

Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A

IF3.9

2016-08-0922

PREAI

Identification of Potential Drug Targets in Cancer Signaling Pathways using Stochastic Logical Models

SCIENTIFIC REPORTS

IF3.9

2016-03-1825

OAAI

Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy

siRNA预暴露对siRNA治疗后续反应的影响

PHARMACEUTICAL RESEARCH

IF4.3

2015-07-019

Hamidreza Montazeri Aliabadi

个人简介

教育背景

工作经历

荣誉奖项

研究方向